Scarica l'app Stockscreener
3.15
0.32%
-0.01
Dopo l'orario di chiusura:
3.29
0.14
+4.44%
Precedente Chiudi:
$3.16
Aprire:
$3.295
Volume 24 ore:
13,408
Relative Volume:
0.37
Capitalizzazione di mercato:
$16.96M
Reddito:
-
Utile/perdita netta:
$-2.17M
Rapporto P/E:
-0.1816
EPS:
-17.3434
Flusso di cassa netto:
$-4.82M
1 W Prestazione:
-0.94%
1M Prestazione:
-32.40%
6M Prestazione:
-17.75%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.15
$3.37
Intervallo di 1 settimana:
$3.0392
$3.375
Portata 52W:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
3.15 | 17.01M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newcelx Ltd Borsa (NCEL) Ultime notizie
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NCEL Should I Buy - Intellectia AI
TradingKey - TradingKey
NewcelX (NASDAQ: NCEL) registers 2.26M shares for resale by investors - Stock Titan
Why NewcelX (NCEL) is still under the radar (Risk Aversion) 2026-05-06Top Analyst Buy Signals - Newser
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - Quantisnow
NewcelX Ltd. (NCEL) updates resale prospectus for up to 500,000 shares - Stock Titan
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05High Interest Stocks - newser.com
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
League Jinn holds 25.3% ownership stake in NewcelX (NCEL) - Stock Titan
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
NLSPW SEC FilingsNEWCELX LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
NCEL | NewcelX Ltd. Ordinary Shares Insider Trading - Quiver Quantitative
NewcelX Ltd. announced that it has received $1.349994 million in funding - marketscreener.com
NCEL - Finviz
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program - TipRanks
Newcelx Reports Financial Results for 2025 an - Moomoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX makes Type 1 diabetes program its 2026 flagship - Stock Titan
Insider Buying: Olivier Samuel Acquires 81,818 Shares of NewcelX Ltd (NCEL) - GuruFocus
NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NewcelX (NCEL) 20-F: Kadimastem merger, heavy losses and funding risk - Stock Titan
NewcelX Ltd. (NCEL) Stock Price Today - MEXC Exchange
NewcelX (NCEL) Trend Analysis | Q1 2025: Earnings ReportDividend Report - Cổng thông tin điện tử tỉnh Lào Cai
NewcelX updates presentation on diabetes therapy collaboration By Investing.com - Investing.com India
Newcelx updates corporate presentation to highlight type 1 diabetes flagship program - marketscreener.com
NewcelX Highlights Type 1 Diabetes Flagship and Eledon Collaboration in Updated April 2026 Presentation - TipRanks
NewcelX updates presentation on diabetes therapy collaboration - Investing.com
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
[6-K] NewcelX Ltd. Current Report (Foreign Issuer) | NCEL SEC FilingForm 6-K - Stock Titan
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - The Manila Times
NewcelX heads to Swiss Biotech with a Type 1 diabetes strategy - Stock Titan
NewcelX (NCEL) Stock Equalweight (Runs Up) 2026-04-18High Interest Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Liora Oren Net Worth (2026) - GuruFocus
Eran Israel Iohan Net Worth (2026) - GuruFocus
Olivier Samuel Net Worth (2026) - GuruFocus
Tamar Galili Net Worth (2026) - GuruFocus
Alexander Zwyer Net Worth (2026) - GuruFocus
Ronen Twito Net Worth (2026) - GuruFocus
Kfir Molakandov Net Worth (2026) - GuruFocus
Michel Revel Net Worth (2026) - GuruFocus
Omri Hagai Net Worth (2026) - GuruFocus
Should I Buy NewcelX (NCEL) Stock Now | Price at $2.58, Up 3.61%Put Spread Alert - Newser
Newcelx Ltd Azioni (NCEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newcelx Ltd Azioni (NCEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):